278 results found.

Neoplasms Clinical Trial using BI 836845

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I Dose Escalation Trial of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours During Escalation and Weekly in Selected Tumour Types During Expansion, With Repeated Administrations in Patients Showing Clinical Benefit..
BI 836845

Breast Neoplasms, Ovarian Neoplasms, Colonic Neoplasms, Prostatic Clinical Trial

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers.

Sexual Dysfunctions, Psychological, Uterine Cervical Neoplasms, O Clinical Trial using GyneGals Support Group

Women's College Hospital - Recruiting 18 years or older.
- A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer.
GyneGals Support Group

Prostatic Neoplasms Clinical Trial using VT-122; Placebo

Vicus Therapeutics - Recruiting 18 years or older.
- A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer.
VT-122; Placebo

Neoplasms Clinical Trial using BIBW 2992; BIBF 1120

Boehringer Ingelheim - Recruiting 18 years or older.
- Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours..
BIBW 2992; BIBF 1120

Neoplasms Clinical Trial using BI 860585; exemestane; paclitaxel

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours.
BI 860585; exemestane; paclitaxel

Leukemia, or Neoplasms Clinical Trial using volasertib

Boehringer Ingelheim - Recruiting 2 years to 17 years.
- Open, Non-controlled, Dose Escalating Phase I Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Tolerability and Toxicity of Volasertib in Paediatric Patients From 2 Years to Less Than 18 Years of Age With Acute Leukaemia or Advanced Solid Tumour, for Whom no Effective Treatment is Known.
volasertib

Neoplasms Clinical Trial using Cetuximab( erbituxr); Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase Ib Dose Escalation Study of Afatinib in Combination With Cetuximab in Patients With Advanced Solid Tumours.
Cetuximab( erbituxr); Afatinib

Head and Neck Neoplasms Clinical Trial using methotrexate; afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy.
methotrexate; afatinib

Neoplasms Clinical Trial using BI 853520

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies.
BI 853520

Head and Neck Neoplasms Clinical Trial using Placebo; Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma.
Placebo; Afatinib

Neoplasms Clinical Trial using Carboplatin; BIBW 2992; Paclitaxel; BIBW2992; Bevacizumab

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I Open Label Trial of Continuous Dosing With BIBW 2992 Combined With Paclitaxel and BIBW 2992 Combined With Paclitaxel and Bevacizumab, BIBW 2992 Combined With Carboplatin and BIBW 2992 Combined With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumours.
Carboplatin; BIBW 2992; Paclitaxel; BIBW2992; Bevacizumab

Neoplasms Clinical Trial using volasertib; itraconazole

Boehringer Ingelheim - Recruiting 18 years to 70 years.
- An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours.
volasertib; itraconazole

Neoplasms Clinical Trial using MPDL3280A; bevacizumab [Avastin]; FOLFOX; carboplatin; paclitaxel; pemetrexed; nab-paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered With Bevacizumab and/or With Chemotherapy in Patients With Advanced Solid Tumors.
MPDL3280A; bevacizumab [Avastin]; FOLFOX; carboplatin; paclitaxel; pemetrexed; nab-paclitaxel

Breast Neoplasms, or Stomach Neoplasms Clinical Trial using Herceptin; afatinib; trastuzumab

Boehringer Ingelheim - Recruiting 18 years or older.
- Phase I Trial of Afatinib in Combination With 3 Weekly Trastuzumab in Patients With Tumours Overexpressing HER2. Once the MTD of Afatinib With 3 Weekly Trastuzumab Was Established the Safety of This Dose Will be Assessed Also in Combination With Weekly Trastuzumab..
Herceptin; afatinib; trastuzumab

Neoplasms Clinical Trial using BI 853520

Boehringer Ingelheim - Recruiting 20 years or older.
- An Open-label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Japanese and Taiwanese Patients With Various Advanced or Metastatic Solid Tumours.
BI 853520

Prostate Cancer, Castration Resistant Prostate Cancer, Pain, or P Clinical Trial using cabozantinib; mitoxantrone; prednisone

Exelixis - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer.
cabozantinib; mitoxantrone; prednisone

Neoplasms Clinical Trial using BI 836845

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Patients With Advanced Solid Cancers With Repeated Administrations in Patients Showing Clinical Benefit.
BI 836845

Skin Cancer Clinical Trial

Memorial Sloan-Kettering Cancer Center - Recruiting 10 years or older.
- In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin.

Neuroendocrine Neoplasms, Thyroid Neoplasms, Parathyroid Neoplasm Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 7 years or older.
- Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms.

Myeloproliferative Neoplasms Clinical Trial using Ruxolitinib; Decitabine

Mount Sinai School of Medicine - Recruiting 18 years or older.
- Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML.
Ruxolitinib; Decitabine

Prostatic Neoplasms Clinical Trial using BAY2010112

Bayer - Recruiting 18 years or older.
- An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY2010112 Given Once Daily by Subcutaneous Administration in Subjects With Castration-resistant Prostate Cancer.
BAY2010112

Neoplasms Clinical Trial using MEHD7945A; cobimetinib

Genentech - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MEHD7945A and GDC-0973 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH MUTANT KRAS.
MEHD7945A; cobimetinib

Colorectal Neoplasms Clinical Trial using Regorafenib (BAY73- 4506)

Bayer - Recruiting 18 years or older.
- An Open-label Phase III Study of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy.
Regorafenib (BAY73- 4506)

Ovarian Cancer, Epithelial Tumors, Malignant, Fallopian Tube Canc Clinical Trial using DNIB0600A; pegylated liposomal doxorubicin

Genentech - Recruiting 18 years or older.
- A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DNIB0600A COMPARED TO PEGYLATED LIPOSOMAL DOXORUBICIN ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER.
DNIB0600A; pegylated liposomal doxorubicin

Neoplasms Clinical Trial using GDC-0973; GDC-0068

Genentech - Recruiting 18 years or older.
- A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors.
GDC-0973; GDC-0068

Neoplasms Clinical Trial using BAY1125976

Bayer - Recruiting 18 years or older.
- A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors.
BAY1125976

Prostatic Neoplasms, or Bone Mineral Density Quantitative Trait L Clinical Trial using vitamin D; Placebo

University of Rochester - Recruiting 60 years or older.
- High-dose Vitamin D Supplementation for ADT-induced Side Effects.
vitamin D; Placebo

Carcinoma, Squamous Cell, Mouth Neoplasms, Oropharyngeal Neoplasm Clinical Trial

Centre Hospitalier Universitaire de NÄ«mes - Recruiting 30 years to 80 years.
- Pharmacogenetic and Pharmacokinetic Aspects of the Response to Chemotherapy Induction Using Docetaxel, Cisplatin and 5-Fluorouracile (TPF)in ORL Cancers.

Prostatic Neoplasms Clinical Trial

Centre Hospitalier Universitaire de NÄ«mes - Recruiting 45 years to 75 years.
- Medico-economic Comparison of Robot-assisted Radical Prostatectomy Using the da Vinci System Versus Radical Prostatectomy Via Laparotomy.

Thyroid Nodule, or Thyroid Neoplasms Clinical Trial using Elastography

Centre Hospitalier Universitaire de NÄ«mes - Recruiting 18 years or older.
- The Role of Elastography in the Diagnosis of Thyroid Nodules.
Elastography

Colorectal Neoplasms Clinical Trial using Samples and follow up

Centre Hospitalier Universitaire de NÄ«mes - Recruiting 18 years or older.
- Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer: Molecular Characterization and Implications for Therapeutic Strategies.
Samples and follow up

Pancreatic Diseases, Pancreatic Neoplasms, or Pancreatitis Clinical Trial using No interventions, this is an observational study

Aalborg Universityhospital - Recruiting 18 years or older.
- Cell-free DNA Promoter Hypermethylation in Plasma From Patients With Pancreatic Adenocarcinoma, Compared to Patients With Pancreatitis and Pancreatitis and Patients Screened for, But Not Having Pancreatic Adenocarcinoma.'.
No interventions, this is an observational study

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (Xofigo, BAY88-8223)

Bayer - Recruiting 18 years or older.
- A Re-treatment Safety Study of Radium-223 Dichloride in Subjects With Castration-resistant Prostate Cancer With Bone Metastases Who Received an Initial Course of Six Doses of Radium-223 Dichloride 50 kBq/kg Every Four Weeks.
Radium-223 dichloride (Xofigo, BAY88-8223)

Neoplasms, Hematologic Clinical Trial using 120 mg LY2784544

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms.
120 mg LY2784544

Neoplasms Clinical Trial using Paclitaxel; Copanlisib (BAY80-6946)

Bayer - Recruiting 18 years or older.
- A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy.
Paclitaxel; Copanlisib (BAY80-6946)

Brain and Central Nervous System Tumors, Intraocular Melanoma, Lu Clinical Trial using DNA analysis; immunologic technique; pharmacological study; iodine I 131 monoclonal antibody 3F8; 131I-3F8

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms.
DNA analysis; immunologic technique; pharmacological study; iodine I 131 monoclonal antibody 3F8; 131I-3F8

Pancreatic Neoplasms Clinical Trial using Oxaliplatin; Irinotecan; Leucovorin; Fluorouracil; laboratory biomarker analysis; flow cytometry; immunohistochemistry staining method; pharmacological study; PF-04136309

Washington University School of Medicine - Recruiting 18 years or older.
- Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Oxaliplatin; Irinotecan; Leucovorin; Fluorouracil; laboratory biomarker analysis; flow cytometry; immunohistochemistry staining method; pharmacological study; PF-04136309

Neoplasms, Pancreas Clinical Trial using cancer stem cell vaccine

Fuda Cancer Hospital, Guangzhou - Recruiting 18 years to 75 years.
- Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Pancreas.
cancer stem cell vaccine

Esophageal Cancer, Bile Duct Neoplasms, Gastric Cancer, Liver Can Clinical Trial

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites..

Neoplasms Clinical Trial using RO5503781

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multi-center, Open Label, First in Human Phase I Dose Escalation Study of Single Agent RO5503781, a Small Molecule MDM2 Antagonist, Administered Orally in Patients With Advanced Malignancies, Except Leukemia.
RO5503781

Neoplasms Clinical Trial using zirconium-89-labeled RO5479599; RO5479599; cetuximab; erlotinib

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase Ia/Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5479599, a Glycoengineered Antibody Against HER3, Administered Either Alone (Part A) or in Combination With Cetuximab (Part B) or in Combination With Erlotininb (Part C) in Patients With Metastatic and/or Locally Advanced Malignant HER3-positive Solid Tumors of Ephitelian Cell Origin.
zirconium-89-labeled RO5479599; RO5479599; cetuximab; erlotinib

Neoplasms Clinical Trial using RO5509554; paclitaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors..
RO5509554; paclitaxel

Neoplasms Clinical Trial using Vemurafenib; Cobimetinib; Onartuzumab

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB IN COMBINATION WITH VEMURAFENIB AND/OR COBIMETINIB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES.
Vemurafenib; Cobimetinib; Onartuzumab

Neoplasms Clinical Trial using RO5503781; posaconazole

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTIPLE-CENTER, OPEN-LABEL CLINICAL PHARMACOLOGY STUDY WITH RO5503781, AN MDM2 ANTAGONIST, IN PATIENTS WITH SOLID TUMORS TO DETERMINE: PART 1 ONE-SEQUENCE, 2-PERIOD CROSSOVER DESIGN TO INVESTIGATE THE EFFECT OF POSACONAZOLE, A STRONG CYP3A4 INHIBITOR, ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF RO5503781 PART 2 A RANDOMIZED, SINGLE DOSE, 3 PERIOD CROSSOVER DESIGN TO INVESTIGATE THE RELATIVE BIOAVAILABILITY OF TWO NEW RO5503781 TABLET FORMULATIONS FOLLOWING ORAL ADMINISTRATION.
RO5503781; posaconazole

Neoplasms Clinical Trial using RO5429083

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors.
RO5429083

Multiple Myeloma, Neoplasms Clinical Trial using Vemurafenib

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers.
Vemurafenib

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (Xofigo, BAY88-8223)

Bayer - Recruiting 18 years or older.
- A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis.
Radium-223 dichloride (Xofigo, BAY88-8223)

Malignant Solid Neoplasms Clinical Trial using Nilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD); Pazopanib (800 mg QD)

Centre Leon Berard - Recruiting 18 years or older.
- A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors.
Nilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD); Pazopanib (800 mg QD)

Neoplasms Clinical Trial using bevacizumab [Avastin]

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open Label Multicentre Extension Study of Bevacizumab Administered as Single Agent or in Combination With Other Anticancer Therapies in Patients on Study Treatment With Bevacizumab at the End of a F. Hoffmann-La Roche and/or Genentech Sponsored Study.
bevacizumab [Avastin]

Stomach Neoplasms; Esophageal Neoplasms; Metastatic Gastric Cance Clinical Trial using AUY922; BYL719

Novartis - Recruiting 18 years or older.
- A Phase IB, Multicenter, Open-label Dose Escalation Study of the PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer Carrying a Molecular Alteration of PIK3CA or an Amplification of HER2.
AUY922; BYL719

Neoplasms Clinical Trial using vemurafenib

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase IV, PostMarketing, Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol.
vemurafenib

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; acenocoumarol

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ACENOCOUMAROL IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY.
vemurafenib; acenocoumarol

Colorectal Neoplasms, Esophageal Neoplasms, or Ovarian Neoplasms Clinical Trial using Indomethacin

UMC Utrecht - Recruiting 18 years to 70 years.
- Phase I Study Evaluating Indomethacin in Combination With Platinum-based Chemotherapy.
Indomethacin

Head and Neck Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 21 years or older.
- Pilot Study to Evaluate the Natural History of Head and Neck Cancer Precursors in Taiwan.

Recurrent Mature B-cell Neoplasms Clinical Trial using PCI-32765

Janssen Pharmaceutical K.K. - Recruiting 20 years or older.
- A Phase 1 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Subjects With Recurrent Mature B-Cell Neoplasms.
PCI-32765

Neoplasms Clinical Trial using Refametinib (BAY86-9766); Gemcitabine

Bayer - Recruiting 18 years or older.
- A Multi-center, Phase Ib Study of MEK (Mitogen Activated Protein Kinase/ERK Kinase) Inhibitor BAY86-9766 Plus Gemcitabine in Asian Patients With Advanced or Refractory Solid Tumors.
Refametinib (BAY86-9766); Gemcitabine

Ovarian Cancer, Cancer of the Ovary, or Ovarian Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Blood From Patients With Ovarian Cancer.

Neoplasms,, Metastatic Cancer,, Non-Small Cell Lung Cancer, or Ad Clinical Trial using AZD6244; Docetaxel

AstraZeneca - Recruiting 20 years or older.
- A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given as a Monotherapy in Japanese Patients With Advanced Solid Malignancies, and When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV).
AZD6244; Docetaxel

Brain Neoplasms, or Central Nervous System Neoplasms Clinical Trial using Everolimus; Sorafenib

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I-II Trial Everolimus and Sorafenib in Patients With Recurrent High-Grade Gliomas.
Everolimus; Sorafenib

Hematologic Neoplasms, Neural Tube Defects, or Myeloproliferative Clinical Trial using therapeutic allogeneic lymphocytes; Sirolimus

National Institutes of Health Clinical Center (CC) - Recruiting 11 years to 90 years.
- Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome.
therapeutic allogeneic lymphocytes; Sirolimus

Small Cell Lung Carcinoma, or Malignant Epithelial Neoplasms Clinical Trial using (Belinostat) (PDX101); Cisplatin; Etoposide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With a Focus on Small Cell Lung Cancer and Other Cancers of Neuroendocrine Origin.
(Belinostat) (PDX101); Cisplatin; Etoposide

Liver Cancer, Neoplasms, Liver, or Hepatic Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Prospective Pilot Observational Study Examining Cone Beam CT and CT Thermometry During Ablations.

Pain, Neoplasms, or Chronic Pain Clinical Trial using Cebranopadol

Grnenthal GmbH - Recruiting 18 years or older.
- An Open-label, Multi-site Trial to Describe the Safety and Tolerability of Oral Cebranopadol Administered for 26 Weeks in Subjects With Cancer-related Pain Who Have Completed Treatment in the KF6005/07 Trial..
Cebranopadol

Neoplasms, or Lymphoma Clinical Trial using MK-1775

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Single-agent MK-1775, a Wee1 Inhibitor, in Patients With Advanced Refractory Solid Tumors.
MK-1775

Neoplasms Clinical Trial using 5-Fluoro-2-Deoxycytidine; Tetrahydrouridine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase I Trial of Oral 5-Fluoro-2-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.
5-Fluoro-2-Deoxycytidine; Tetrahydrouridine

Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasm Clinical Trial using 5-Fluoro-2-Deoxycytidine (FdCyd); Tetrahydrouridine (THU)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU).
5-Fluoro-2-Deoxycytidine (FdCyd); Tetrahydrouridine (THU)

Myelodysplastic Syndrome (MDS), Hematologic Neoplasms, Hematologi Clinical Trial using Cord Blood Transplant

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications.
Cord Blood Transplant

Lung or Prostatic Neoplasms, Colorectal or Kidney Neoplasms, Panc Clinical Trial using NK cells +CliniMACs CD3 and CD56 systems

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib.
NK cells +CliniMACs CD3 and CD56 systems

Epithelial Neoplasms, Malignant, Epithelial Tumors, Malignant, or Clinical Trial using NHS-IL-12

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- First In-Human Phase I Trial of NHS-IL12 in Subjects With Metastatic Solid Tumors.
NHS-IL-12

Lung Neoplasms, Liver Neoplasms, Kidney Neoplasms, or Cancer Clinical Trial using Laser-Assisted Angle Selection System; Block-Assisted Angle Selection System

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Comparison of Methods for Assisting Needle Angle Selection During Image-Guided Tissue Biopsy.
Laser-Assisted Angle Selection System; Block-Assisted Angle Selection System

Neoplasms Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting 16 years or older.
- Sorafenib Long Term Extension Program.
Sorafenib (Nexavar, BAY43-9006)

Neoplasms, Nervous System Disease, or Vestibular Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- Using Positron Emission Tomography (PET) to Predict Intracranial Tumor Growth in Neurofibromatosis Type II (NF2) Patients.

Li-Fraumeni Syndrome, Neoplasms, or Tp53 Mutations Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 3 years or older.
- Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome.

Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasm Clinical Trial using Tetrahydrouridine (THU); [F-18]-5-FLUORO-2'-DEOXYCYTIDINE

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine.
Tetrahydrouridine (THU); [F-18]-5-FLUORO-2'-DEOXYCYTIDINE

Lung Neoplasms Clinical Trial using Radiation Concurrent Chemotherapy

Proton Collaborative Group - Recruiting 18 years or older.
- A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer.
Radiation Concurrent Chemotherapy

Pain, Neoplasms, or Chronic Pain Clinical Trial using Cebranopadol; Morphine Prolonged Release

Grnenthal GmbH - Recruiting 18 years or older.
- Efficacy, Safety, and Tolerability of Oral Cebranopadol Versus Morphine Sulfate PR in Subjects With Chronic Moderate to Severe Pain Related to Cancer..
Cebranopadol; Morphine Prolonged Release

Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Blood, Tissue and Urine From Patients With Cancer.

Neoplasms, or Lymphoma Clinical Trial using LMP 400; LMP 776

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas.
LMP 400; LMP 776

Colorectal Neoplasms, Gastric Neoplasms, Cholangiocarcinoma, Bile Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- Tumor, Normal Tissue and Specimens From Patients Undergoing Evaluation or Surgical Resection of Solid Tumors.

Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Can Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer.

Sarcoma, Stomach Neoplasms, or Neoplasms Clinical Trial using Pazopanib; ARQ 197

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors.
Pazopanib; ARQ 197

Breast Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 74 years.
- A Multidisciplinary Study of Breast Cancer in Ghana: Pilot Phase.

HIV Infections, Central Nervous System Neoplasms, or Neurofibroma Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Analysis of Stored Data Collected From Individuals Administered Neurobehavioral Assessments on IRB-Approved Protocols.

Breast Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 30 years to 70 years.
- The Ultrasound Study of Tamoxifen.

Prostatic Neoplasms Clinical Trial using Cabozantinib; Docetaxel; Prednisone

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer.
Cabozantinib; Docetaxel; Prednisone

Neoplasms Clinical Trial using Temozolomide; Everolimus; Carboplatin; Trametinib DMSO; ABT-888; MK-1775

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors.
Temozolomide; Everolimus; Carboplatin; Trametinib DMSO; ABT-888; MK-1775

Ovarian Neoplasms, Peritoneal Neoplasms, or Fallopian Tube Neopla Clinical Trial using Trabectedin; DOXIL; Dexamethasone

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Trabectedin; DOXIL; Dexamethasone

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (Xofigo, BAY88-8223)

Bayer - Recruiting 20 years or older.
- A Single-arm, Open-label, Multicenter, Phase II Study of BAY88-8223 in the Treatment of Japanese Patients With Symptomatic Castration-resistant Prostate Cancer (CRPC) With Bone Metastases.
Radium-223 dichloride (Xofigo, BAY88-8223)

Neoplasms Clinical Trial using Everolimus

Novartis - Recruiting N/A or older.
- An Open Label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment.
Everolimus

Myeloproliferative Neoplasms of, Polycythemia Vera, Essential Thr Clinical Trial using LY2784544

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms.
LY2784544

Colorectal Neoplasms Clinical Trial using folic acid; folic acid calcium vitamin D3; calcium

Shanghai Jiao Tong University School of Medicine - Recruiting 50 years to 80 years.
- A Randomize Controlled Trial of Folic Acid, Calcium and Vitamin D in Preventing Colorectal Polyps and Colorectal Cancer.
folic acid; folic acid calcium vitamin D3; calcium

Breast Neoplasms, or Breast Cancer Clinical Trial using Taxane; Taxotere; Abraxane; Ixabepilone

The Methodist Hospital System - Recruiting 18 years or older.
- Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy..
Taxane; Taxotere; Abraxane; Ixabepilone

Breast Neoplasms, BRCA 1 Gene Mutation, or BRCA 2 Gene Mutation Clinical Trial using BMN 673; Physician's-Choice

BioMarin Pharmaceutical - Recruiting 18 years or older.
- A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 Versus Physician's Choice in Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More Than 2 Prior Chemotherapy Regimens for Metastatic Disease.
BMN 673; Physician's-Choice

Neoplasms Clinical Trial using RO6895882

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION, PHASE I STUDY WITH AN EXPANSION PHASE, TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6895882, AN IMMUNOCYTOKINE, CONSISTING OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN (CEA) ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS.
RO6895882

Neoplasms Clinical Trial using RO5520985

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Multi-center, Dose Escalation Phase I Study of Single Agent RO5520985, Administered as an Intravenous Infusion in Patients With Locally Advanced or Metastatic Solid Tumors..
RO5520985

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (BAY88-8223)

Bayer - Recruiting 18 years or older.
- Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases.
Radium-223 dichloride (BAY88-8223)

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (Xofigo,BAY88-8223); Abiraterone acetate; Prednisone; Enzalutamide

Bayer - Recruiting 18 years or older.
- A Randomized Open-label Phase IIa Study Evaluating the Efficacy and Safety of Radium-223 Dichloride in Combination With Abiraterone Acetate or Enzalutamide in Subjects With CRPC Who Have Bone Metastases.
Radium-223 dichloride (Xofigo,BAY88-8223); Abiraterone acetate; Prednisone; Enzalutamide

Colorectal Neoplasms Clinical Trial using Regorafenib (Stivarga, BAY73-4506); Placebo

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases.
Regorafenib (Stivarga, BAY73-4506); Placebo

Neoplasms Clinical Trial using Regorafenib (Stivarga, BAY73-4506)

Bayer - Recruiting 18 years or older.
- A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group.
Regorafenib (Stivarga, BAY73-4506)

Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutatio Clinical Trial using Botulinum Toxin Type A; Sodium Chloride Solution

Mayo Clinic - Recruiting 18 years or older.
- Botulinum Toxin A in Tissue Expander Breast Reconstruction: A Double-Blinded Randomized Controlled Trial.
Botulinum Toxin Type A; Sodium Chloride Solution

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; tizanidine

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- A PHASE I, OPEN-LABEL, MULTICENTER, 3- PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF SINGLE DOSE OF TIZANIDINE (A CYP1A2 SUBSTRATE) IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY.
vemurafenib; tizanidine

Neoplasms, or Lymphoma Clinical Trial using Part 1: JNJ-42756493; Part 2: JNJ-42756493

Janssen Research & Development, LLC - Recruiting 20 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma.
Part 1: JNJ-42756493; Part 2: JNJ-42756493

Neoplasms, Breast Clinical Trial using lapatinib; trastuzumab; Aromatase inhibitor

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase III Trial to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus an Aromatase Inhibitor (AI) vs. Trastuzumab Plus an AI vs. Lapatinib Plus an AI as 1st- or 2nd- Line Therapy in Postmenopausal Subjects With Hormone Receptor+, HER2+ Metastatic Breast Cancer (MBC) Who Received Prior Trastuzumab and Endocrine Therapies.
lapatinib; trastuzumab; Aromatase inhibitor

Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemi Clinical Trial using cytology specimen collection procedure

Children's Oncology Group - Recruiting N/A to 30 years.
- A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors.
cytology specimen collection procedure

Breast Neoplasms Clinical Trial using Neratinib

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase II Study of Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer.
Neratinib

Stomach Neoplasms Clinical Trial using AMG 337

Amgen - Recruiting 18 years or older.
- A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in Subjects With MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors.
AMG 337

Breast Neoplasms, BRCA 1 Gene Mutation, or BRCA 2 Gene Mutation Clinical Trial using BMN 673

BioMarin Pharmaceutical - Recruiting 18 years or older.
- A Phase 2, 2-Stage, 2-Cohort Study of BMN 673 in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation.
BMN 673

Head and Neck Cancer, Lung Cancer, Lip Cancer, Lip Neoplasms, or Clinical Trial using Tumor biopsy; Phlebotomy

Stanford University - Recruiting 18 years or older.
- Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers.
Tumor biopsy; Phlebotomy

Thymoma, or Thymus Neoplasms Clinical Trial using Sunitinib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy.
Sunitinib

Lung Neoplasms Clinical Trial

Chinese Alliance Against Lung Cancer - Recruiting 40 years to 75 years.
- Multicenter Study for Risk Stratification of Patients Presenting With Symptoms Related to Lung Cancer Using the Lung Cancer Biomarker Panel (LCBP) in China.

Biliary Tract Neoplasms, Neoplasms, Gastrointestinal Diseases, Di Clinical Trial using Evolutionr Biliary Stent - Uncovered

Cook - Recruiting 18 years or older.
- Palliation of Biliary Neoplasms With the Cook Evolutionr Biliary Stent System.
Evolutionr Biliary Stent - Uncovered

Prostatic Neoplasms, or Prostate Cancer Clinical Trial

Stanford University - Recruiting 18 years or older.
- Quality of Life Following Radical Prostatectomy.

Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Clinical Trial using sipuleucel-T

Dendreon - Recruiting 18 years or older.
- An Open-Label Study Study of Sipuleucel-T in European Men With Metastatic, Castrate Resistant Prostate Cancer.
sipuleucel-T

Neoplasms Clinical Trial using BAY1163877

Bayer - Recruiting 18 years or older.
- An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors.
BAY1163877

Malignant Neoplasms Brain Clinical Trial using RNA-loaded dendritic cell vaccine; basiliximab

Duke University - Recruiting 18 years or older.
- REGULATory T-Cell Inhibition With Basiliximab (Simulectr) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme.
RNA-loaded dendritic cell vaccine; basiliximab

Prostatic Neoplasms, or Prostate Cancer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies.

Breast Neoplasms Clinical Trial using Aromasin (exemestane)

Pfizer - Recruiting 18 years or older.
- A Prospective Non-Interventional Study Of China Early Invasive Breast Cancer Patients Receiving Adjuvant Therapy With Aromasinr.
Aromasin (exemestane)

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; phenprocoumon

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- A PHASE I, OPEN-LABEL, MULTICENTER, RANDOMINZED, PARALELL STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF PHENPROCOUMON IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY.
vemurafenib; phenprocoumon

Neoplasms Clinical Trial using Cobimetinib; MPDL3280A

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors.
Cobimetinib; MPDL3280A

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; digoxin

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicenter, 3-Period, Fixed-Sequence Study To Investigate The Effect Of Vemurafenib On The Pharmacokinetics Of A Single Dose Of Digoxin In Patients With BRAFV600 Mutation-Positive Metastatic Malignancy.
vemurafenib; digoxin

Breast Neoplasms Clinical Trial using Sorafenib (Nexavar, BAY43-9006); Eribulin

Bayer - Recruiting 18 years or older.
- A Phase 1, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Sorafenib (BAY43-9006) in Combination With Eribulin in Subjects With Advanced, Metastatic or Refractory Solid Tumors.
Sorafenib (Nexavar, BAY43-9006); Eribulin

Adenocarcinoma, or Pancreatic Neoplasms Clinical Trial using X-82; Everolimus

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors.
X-82; Everolimus

Colorectal Neoplasms Clinical Trial using Endoscopic submucosal dissection; Laparoscopic resection

Chinese University of Hong Kong - Recruiting 18 years or older.
- Endoscopic Submucosal Dissection Versus Laparoscopic Resection for Early Colorectal Neoplasms: A Prospective Randomized Trial.
Endoscopic submucosal dissection; Laparoscopic resection

Prostate Cancer, or Prostatic Neoplasms Clinical Trial using Panobinostat; Bicalutamide

New York University School of Medicine - Recruiting 18 years or older.
- Phase I/II Randomized Trial of LBH589 (Panobinostat) at Two Dose Levels Combined With Bicalutamide (Casodex) in Men With Castration-resistant Prostate Cancer.
Panobinostat; Bicalutamide

Endometrial Neoplasms Clinical Trial using PF-05212384

Pfizer - Recruiting 20 years or older.
- A Randomized Phase 2 Non-Comparative Study Of The Efficacy Of PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer.
PF-05212384

Systemic Anaplastic Large-Cell Lymphoma, Neoplasms, Anaplastic Ly Clinical Trial using PF-02341066; Rifampin; Ketoconazole

Pfizer - Recruiting 18 years or older.
- Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of PF-02341066, A c-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer.
PF-02341066; Rifampin; Ketoconazole

Kidney Neoplasms Clinical Trial using Sunitinib malate; Placebo

Pfizer - Recruiting 18 years or older.
- Sunitinib Treatment Of Renal Adjuvant Cancer (S-TRAC): A Randomized Double Blind Phase 3 Study Of Adjuvant Sunitinib VS. Placebo In Subjects At High Risk Of Recurrent RCC.
Sunitinib malate; Placebo

Colorectal Neoplasms Clinical Trial using Capecitabine

Sun Yat-sen University - Recruiting 18 years to 80 years.
- Phase II Clinical Trial: Capecitabine Maintenance Therapy in Colorectal Cancer Patients With Stage IIIC and R0-R1 Resected Stage IV.
Capecitabine

Hepatoma, Liver Neoplasms, Adenoma, Liver Cell, or Carcinoma, Hep Clinical Trial using TRC 105; Sorafenib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I/II Study of TRC105 in Combination With Sorafenib in Hepatocellular Carcinoma (HCC).
TRC 105; Sorafenib

Prostate Neoplasms, or Prostate Cancer Clinical Trial using Cohort 4; Cohort 3; Cohort 2; Cohort 1

Cougar Biotechnology, Inc. - Recruiting 18 years or older.
- A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Cohort 4; Cohort 3; Cohort 2; Cohort 1

Lung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Ne Clinical Trial using Mithramycin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum.
Mithramycin

Neoplasms Clinical Trial using BAY1082439

Bayer - Recruiting 21 years or older.
- An Open Label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1082439 Given Once Daily in Subjects With Advanced Malignancies.
BAY1082439

Breast Neoplasms Clinical Trial using Vinorelbine 25 mg/m2 weekly; Afatinib 40mg once daily (OD); Paclitaxel 80 mg/m2 weekly

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the Neoadjuvant and/or Adjuvant Treatment Setting.
Vinorelbine 25 mg/m2 weekly; Afatinib 40mg once daily (OD); Paclitaxel 80 mg/m2 weekly

Neoplasms Clinical Trial using bevacizumab plus docetaxel

Tampere University Hospital - Recruiting 18 years or older.
- Single Arm Study of the Combination of Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer.
bevacizumab plus docetaxel

Melanoma, Breast Neoplasms, Lobular Carcinoma, Triple-negative Br Clinical Trial using LGK974

Novartis - Recruiting 18 years or older.
- A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands.
LGK974

Cholangiocarcinoma, or Liver Neoplasms Clinical Trial using Floxuridine; Dexamethasone; Gemcitabine; Oxaliplatin

Washington University School of Medicine - Recruiting 18 years or older.
- Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma.
Floxuridine; Dexamethasone; Gemcitabine; Oxaliplatin

Neoplasms Clinical Trial using ZSTK474

Zenyaku Kogyo Co., Ltd. - Recruiting 20 years or older.
- A Phase 1, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ZSTK474 in Japanese Patients With Advanced Solid Malignancies.
ZSTK474

Carcinoma, Squamous Cell, Head and Neck Neoplasms, or Oropharynge Clinical Trial using Assessment of Oral HPV Infection

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Monitoring of Oral HPV Infection in HPV-positive Oropharyngeal Squamous Cell Carcinoma During and After Chemoradiotherapy (CRT).
Assessment of Oral HPV Infection

Prostatic Neoplasms Clinical Trial using CFG920

Novartis - Recruiting 18 years or older.
- A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer.
CFG920

Neoplasms, Breast Clinical Trial using GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Placebo

GlaxoSmithKline - Recruiting 18 years or older.
- Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer.
GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Placebo

Cancer of the Cervix, or Cervical Neoplasms Clinical Trial using Boost radiation

Duke University - Recruiting 18 years or older.
- Integrated Dose Escalation for Advanced, Localized Cervical Cancer (The IDEAL - Cervix Trial).
Boost radiation

Neoplasms by Site Clinical Trial using BMS-986016; BMS-936558

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors.
BMS-986016; BMS-936558

Pancreatic Neoplasms Clinical Trial using Ascorbate; Gemcitabine; Radiation therapy

University of Iowa - Recruiting 18 years or older.
- Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I.
Ascorbate; Gemcitabine; Radiation therapy

Prostatic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Mela Clinical Trial using Interactive Voice Response (IVR) Reminders

Michigan State University - Recruiting 21 years or older.
- Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR.
Interactive Voice Response (IVR) Reminders

Barrett's Esophagus, or Esophageal Neoplasms Clinical Trial using Radiofrequency Ablation(RFA) by HALO device.; Endoscopic mucosal resection(EMR) by mucosectomy kit.

Midwest Biomedical Research Foundation - Recruiting 18 years or older.
- Endoscopic Resection or Ablation for Patients With Dysplasia or Intramucosal Cancer in Barrett's Esophagus.
Radiofrequency Ablation(RFA) by HALO device.; Endoscopic mucosal resection(EMR) by mucosectomy kit.

Ovarian Cancer, Peritoneal Neoplasms Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Non-interventional Trial With Avastin as Front-line Treatment for Ovarian Cancer.

Peritoneal Neoplasms Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Surveillance Study (NIS) on First-line (FL) Bevacizumab (Avastin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Neoplasms Clinical Trial using vemurafenib

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients.
vemurafenib

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; rifampin

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Rifampin On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib.
vemurafenib; rifampin

Thyroid Neoplasms Clinical Trial using Ponatinib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer.
Ponatinib

Neoplasms, Neoplasm Metastasis, or Lymphoma Clinical Trial using LY3039478

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer.
LY3039478

Neoplasms, Neoplasm Metastasis, Melanoma, Carcinoma, Non-Small-Ce Clinical Trial using LY3009120 capsule

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer.
LY3009120 capsule

Colorectal Neoplasms Clinical Trial using Geriatric intervention

Oslo University Hospital - Recruiting 65 years or older.
- Geriatric Intervention in Elderly Surgical Patients With Colorectal Cancer - a Randomized, Controlled Trial..
Geriatric intervention

Neoplasms Clinical Trial using IMC-3C5

Eli Lilly and Company - Recruiting 18 years or older.
- Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available.
IMC-3C5

Neoplasms, Brain Clinical Trial using Dabrafenib 3 mg/kg; Dabrafenib 3.75 mg/kg; Dabrafenib 4.5 mg/kg; Dabrafenib 1.5 mg/kg; Dabrafenib 2.25 mg/kg; Dabrafenib (Final selected dose from Part 1)

GlaxoSmithKline - Recruiting 1 Month to 17 years.
- Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years With Advanced BRAF V600-Mutation Positive Solid Tumors.
Dabrafenib 3 mg/kg; Dabrafenib 3.75 mg/kg; Dabrafenib 4.5 mg/kg; Dabrafenib 1.5 mg/kg; Dabrafenib 2.25 mg/kg; Dabrafenib (Final selected dose from Part 1)

Mouth Neoplasms, Head and Neck Neoplasms, Tongue Neoplasms, or Ca Clinical Trial using Rapamycin; Biopsy; Dynamic CT Perfusion; Positron Emission Tomography; Measurement Serum Cytokines

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 80 years.
- A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer.
Rapamycin; Biopsy; Dynamic CT Perfusion; Positron Emission Tomography; Measurement Serum Cytokines

Neoplasms Clinical Trial using Regorafenib (Stivarga, BAY73-4506); Cetuximab (ERBITUX)

Bayer - Recruiting 18 years or older.
- A Phase 1b, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY73-4506) in Combination With Cetuximab in Subjects With Locally Advanced or Metastatic Solid Tumors Who Are Not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as a Standard Treatment.
Regorafenib (Stivarga, BAY73-4506); Cetuximab (ERBITUX)

Neoplasms, Oral, or Mouth Neoplasms Clinical Trial using GSK1120212

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase II Window of Opportunity Trial With GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer.
GSK1120212

Oropharyngeal Neoplasms Clinical Trial using Intensity-modulated radiation therapy (IMRT); Cisplatin

Washington University School of Medicine - Recruiting 21 years or older.
- Adjuvant De-escalation, Extracapsular Spread, P16+, Transoral (A.D.E.P.T.) Trial for Oropharynx Malignancy.
Intensity-modulated radiation therapy (IMRT); Cisplatin

Breast Neoplasms, or Healthy Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Characterization of High Risk Breast Duct Epithelium by Cytology, Breast Duct Endoscopy, and cDNA Gene Expression Profile.

Breast Neoplasms, or Ovarian Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer.

Leiomyomatosis, or Kidney Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer.

Prostate Cancer, or Prostatic Neoplasms Clinical Trial using Visualase Thermal Therapy System

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- MR Image Guided Focal Therapy in Prostate Cancer.
Visualase Thermal Therapy System

Head and Neck Neoplasms Clinical Trial using Ketogenic diet

University of Iowa - Recruiting 18 years or older.
- A Phase I Trial of a Ketogenic Diet With Concurrent Chemoradiation for Head and Neck Cancer.
Ketogenic diet

Neoplasms Clinical Trial using Tariquidar; Tc-94m Sestamibi; positron emission tomography; radionuclide imaging

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot Study of Tc-94m Sestamibi PET MDR Imaging.
Tariquidar; Tc-94m Sestamibi; positron emission tomography; radionuclide imaging

Hormone Receptor-Positive Breast, Gynecologic, Desmoid, or Hormon Clinical Trial using z-Endoxifen; [(18)F] Fluoroestradiol

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors.
z-Endoxifen; [(18)F] Fluoroestradiol

Colorectal Neoplasms, Colorectal Carcinoma, or Colorectal Tumors Clinical Trial using ISIS 183750; Irinotecan

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer.
ISIS 183750; Irinotecan

Liver Neoplasms, Hepatic Cancer, or Liver Cancer Clinical Trial using Thermal Ablation; Standard External Beam Radiation Therapy

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 64 years.
- Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms.
Thermal Ablation; Standard External Beam Radiation Therapy

Neoplasms Clinical Trial using PF-06263507

Pfizer - Recruiting 18 years or older.
- A Phase 1, Dose Escalation Study Of PF-06263507 In Patients With Advanced Solid Tumors.
PF-06263507

Breast Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Pancre Clinical Trial using ý1ýPb-TCMC-Trastuzumab; trastuzumab

Areva Med LLC - Recruiting 19 years or older.
- Phase I Trial of Intraperitoneal ý1ýPb-TCMC-Trastuzumab for HER-2 Expressing Malignancy.
ý1ýPb-TCMC-Trastuzumab; trastuzumab

Breast Neoplasms Clinical Trial using Trastuzumab; pertuzumab; lapatinib

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib.
Trastuzumab; pertuzumab; lapatinib

Cancer, Metastases, or Liver Neoplasms Clinical Trial using Liver MRI with Gdfos; Liver MRI with EcGd

Sunnybrook Health Sciences Centre - Recruiting 18 years or older.
- Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial.
Liver MRI with Gdfos; Liver MRI with EcGd

Brain Neoplasms, or Surgery Clinical Trial using dexmedetomidine; normal saline

China Medical University, China - Recruiting 35 years to 65 years.
- Randomized, Parallelled and Double-blinded Trial of Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia.
dexmedetomidine; normal saline

Esophageal Fistula, Esophageal Neoplasms, Esophageal Perforation, Clinical Trial using Evolutionr Esophageal Stent - Fully Covered

Cook - Recruiting 18 years or older.
- Clinical Investigation to Evaluate Removal of the Evolutionr Esophageal Stent - Fully Covered.
Evolutionr Esophageal Stent - Fully Covered

Neoplasms Clinical Trial using BAY1000394

Bayer - Recruiting 18 years or older.
- An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies.
BAY1000394

Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junc Clinical Trial using DKN-01; Paclitaxel

Dekkun Corporation - Recruiting 30 years or older.
- A Two Part, Phase 1, Multi-Center, Open-Label Study of DKN-01 in Combination With Weekly Paclitaxel in Patients With Relapsed or Refractory Esophageal Cancer or Gastro-Esophageal Junction Tumors.
DKN-01; Paclitaxel

Prostate Cancer, Castration Resistant Prostate Cancer, or Prostat Clinical Trial using cabozantinib; abiraterone; prednisone

Exelixis - Recruiting 18 years or older.
- A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Na‹ve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer.
cabozantinib; abiraterone; prednisone

Prostate Neoplasms Clinical Trial using Abiraterone acetate; Prednisone; ADT (androgen deprivation therapy); Placebo

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC).
Abiraterone acetate; Prednisone; ADT (androgen deprivation therapy); Placebo

Neoplasms Clinical Trial using 4 mg/kg Onartuzumab (MetMAb); 15 mg/kg Onartuzumab (MetMAb); 30 mg/kg Onartuzumab (MetMAb)

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE I STUDY OF THE PHARMACOKINETICS AND SAFETY OF ONARTUZUMAB IN CHINESE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS.
4 mg/kg Onartuzumab (MetMAb); 15 mg/kg Onartuzumab (MetMAb); 30 mg/kg Onartuzumab (MetMAb)

Neoplasms Clinical Trial using Afatinib; docetaxel; gemcitabine

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- A Phase I Dose Escalation Trial of Once Daily Oral Treatment Using Afatinib (BIBW2992) Plus Gemcitabine or Docetaxel in Patients With Relapsed or Refractory Solid Tumors..
Afatinib; docetaxel; gemcitabine

Breast Neoplasms Clinical Trial using Letrozole

Samuel Lunenfeld Research Institute, Mount Sinai Hospital - Recruiting N/A or older.
- Patient-related Predictors of Estrogen Suppression in Postmenopausal Women Using Adjuvant Letrozole.
Letrozole

Acute Myeloid Leukemia, Infantile Leukemia (Both AML and ALL), My Clinical Trial using Sorafenib; Cytarabine; Clofarabine

St. Jude Children's Research Hospital - Recruiting N/A to 31 years.
- A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies.
Sorafenib; Cytarabine; Clofarabine

Esophageal Neoplasms Clinical Trial using Pronase; Control No pronase plus Dimethicone and sodium bicarbonate

Xijing Hospital of Digestive Diseases - Recruiting 18 years to 75 years.
- .
Pronase; Control No pronase plus Dimethicone and sodium bicarbonate

Breast Neoplasms Clinical Trial

Medical University of Graz - Recruiting 18 years to 80 years.
- Prospective Validation of Genomic Signatures to Predict Treatment Response in the Axillary Nodes After Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer.

Nausea, Vomiting, or Genital Neoplasms, Female Clinical Trial using Fosaprepitant dimeglumine; Placebo

Odense University Hospital - Recruiting 18 years or older.
- A Multinational, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Tolerability of Palonosetron and Dexamethasone Plus Fosaprepitant or Placebo in Patients Receiving Radiotherapy and Weekly Cisplatin..
Fosaprepitant dimeglumine; Placebo

Neoplasms Clinical Trial using BAY1143572

Bayer - Recruiting 21 years or older.
- An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Malignancies.
BAY1143572

Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm Clinical Trial using Alisertib; Pazopanib

University of Illinois at Chicago - Recruiting 18 years or older.
- Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors.
Alisertib; Pazopanib

Esophageal Cancer, Esophageal Dysplasia, Stomach Cancer, or Stoma Clinical Trial using Hybrid knife; IT knife

Xijing Hospital of Digestive Diseases - Recruiting 18 years to 80 years.
- Comparison of O-type Hybrid Knife and IT Knife in Endoscopic Submucosal Dissection for Upper Gastrointestinal Neoplasms: a Prospective Randomized Controlled Trial.
Hybrid knife; IT knife

Colorectal Neoplasms Clinical Trial using BAY73-4506_Regorafenib

Bayer - Recruiting N/A or older.
- Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer.
BAY73-4506_Regorafenib

Appendix Cancer, or Colorectal Cancer Clinical Trial using Cytoreductive Surgery; HIPEC with Mitomycin-C; EPIC with FUDR and Leucovorin

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Single-center, Randomized Phase II Trial of Early Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis.
Cytoreductive Surgery; HIPEC with Mitomycin-C; EPIC with FUDR and Leucovorin

Head and Neck Neoplasms, Neoplasm Metastasis, Recurrent Disease, Clinical Trial using BKM120

Centre Leon Berard - Recruiting 18 years or older.
- A Phase II, Multicenter Trial Aiming to Evaluate the Clinical Interest of a Monotherapy With BKM120 , a PI3K Inhibitor in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive Under Platin and Cetuximab-based Chemotherapy.
BKM120

Breast Neoplasms Clinical Trial using Doxorubicin; Trastuzumab; Cyclophosphamide; Paclitaxel

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells.
Doxorubicin; Trastuzumab; Cyclophosphamide; Paclitaxel

Colorectal Neoplasms Clinical Trial using Eflornithine placebo & sulindac placebo; eflornithine & sulindac placebo; Eflornithine placebo & sulindac; Eflornithine plus sulindac

Southwest Oncology Group - Recruiting 18 years or older.
- A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES).
Eflornithine placebo & sulindac placebo; eflornithine & sulindac placebo; Eflornithine placebo & sulindac; Eflornithine plus sulindac

Neoplasms, Breast Clinical Trial

GlaxoSmithKline - Recruiting 18 years or older.
- A Prospective, Exploratory Observational Study Evaluating Specific Biomarkers in Primary Invasive Breast Cancer and Their Modulation by Standard Neoadjuvant Therapy.

Breast Neoplasms, HER2 Protein, Human, or Geriatric Health Servic Clinical Trial using Lapatinib; Trastuzumab; laboratory biomarker analysis; pharmacological study

City of Hope Medical Center - Recruiting 60 years or older.
- Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer.
Lapatinib; Trastuzumab; laboratory biomarker analysis; pharmacological study

Peutz-Jeghers Syndrome, Neoplastic Processes, or Neoplasm Metasta Clinical Trial using Everolimus

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) - Recruiting 18 years or older.
- Pilot Study of Everolimus in the Treatment of Neoplasms in Patients With Peutz-Jeghers Syndrome.
Everolimus

Brain and Central Nervous System Tumors, Neuroblastoma, or Sarcom Clinical Trial using iodine I 131 monoclonal antibody 8H9

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms.
iodine I 131 monoclonal antibody 8H9

Neoplasms Clinical Trial using buccal swabs and obtaining peripheral blood

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Oncology/Bone Marrow Transplantation Patients.
buccal swabs and obtaining peripheral blood

Cancer of the Liver, Liver Cancer, Hepatoma, Liver Neoplasms, or Clinical Trial using Salmonella typhimurium

Masonic Cancer Center, University of Minnesota - Recruiting 18 years or older.
- A Phase 1 Study of an IL-2 Expressing, Attenuated Salmonella Typhimurium in Patients With Unresectable Hepatic Spread From Any Non-Hematologic Primary.
Salmonella typhimurium

Neoplasms Clinical Trial using BAY80-6946 + BAY86-9766

Bayer - Recruiting 18 years or older.
- Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer.
BAY80-6946 + BAY86-9766

Neoplasms, or Hematologic Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples From Patients With Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members.

Lung and Pleural Malignancies, Neoplasms, or Nodules Clinical Trial using EC17

University of Pennsylvania - Recruiting 18 years or older.
- Pilot and Feasibility Study of the Imaging Potential of EC17.
EC17

Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, B Clinical Trial using 5-ALA (Gliolan)

Emory University - Recruiting 18 years or older.
- WCI1999-11: A Phase II Study of 5-Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Newly Diagnosed or Recurrent Malignant Gliomas.
5-ALA (Gliolan)

Lung Neoplasms Clinical Trial using Sublobar Resection; Stereotactic Body Radiotherapy (SBRT)

Mayo Clinic - Recruiting 18 years or older.
- Randomized Phase II Trial of Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients With Early Stage Non-Small Lung Cancer (NSCLC).
Sublobar Resection; Stereotactic Body Radiotherapy (SBRT)

Colorectal Neoplasms Clinical Trial using Nadroparin; Placebo

Fudan University - Recruiting 18 years to 80 years.
- Study of The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Colorectal Cancer.
Nadroparin; Placebo

Uterine Cervical Neoplasms, Endometrial Neoplasms, Anus Neoplasms Clinical Trial using Bone marrow sparing IMRT radiation therapy

University of Iowa - Recruiting 18 years or older.
- Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging.
Bone marrow sparing IMRT radiation therapy

Carcinomas (Including Squamous Cell and Adenocarcinoma), or Neopl Clinical Trial using blood draw

Stanford University - Recruiting 18 years or older.
- Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy.
blood draw

Breast Neoplasms Clinical Trial

Norwegian University of Science and Technology - Recruiting 18 years or older.
- HR MAS MR Spectroscopy of Breast Cancer Tissue.

Colorectal Neoplasms Clinical Trial using Optimized ESD with snaring; Conventional ESD

Asan Medical Center - Recruiting 18 years or older.
- Comparison of Coventional Endoscopic Submucosal Dissection and Optimized Endoscopic Submucosal Dissection With Snaring for Colorectal Neoplasm.
Optimized ESD with snaring; Conventional ESD

Colorectal Neoplasms, or Metastatic Disease Clinical Trial using Regorafenib

Spanish Cooperative Group for Digestive Tumour Therapy (TTD) - Recruiting 18 years or older.
- A Phase II Study of Single-agent Regorafenib in the First Line Treatment of Frail and/or Unfit for Polychemotherapy Patients With Metastatic Colorectal Cancer (mCRC).
Regorafenib

Cervical Neoplasms Clinical Trial using tri-weekly cisplatin-based chemoradiation

Korea Cancer Center Hospital - Recruiting N/A or older.
- Phase II Clinical Trial for Adjuvant Concurrent Chemoradiation Therapy in Post-operative Cervical Cancer Patients.
tri-weekly cisplatin-based chemoradiation

Neoplasms Clinical Trial using Everolimus; Sandostatin LAR Depot

Novartis - Recruiting N/A or older.
- An Open-label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment.
Everolimus; Sandostatin LAR Depot

Breast Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Clinical Trial using Botulinum Toxin-A; Saline

University of British Columbia - Recruiting 21 years or older.
- The Use of Botulinum Toxin-A in Two-stage Tissue Expander/Implant Breast Reconstruction: A Prospective, Randomized, Double-Blind Placebo Controlled Trial.
Botulinum Toxin-A; Saline

Breast Neoplasms Clinical Trial

University Medical Centre Groningen - Recruiting 18 years or older.
- Study of the Cardiovascular and Psychosocial Effects of the Treatment of Breast Cancer With Chemotherapy and/or Radiotherapy.

Malnourished, Stomach Neoplasms, or Gastrointestinal Stromal Tumo Clinical Trial using Ensure powder

Seoul National University Hospital - Recruiting 20 years or older.
- A Prospective Randomized Controlled Trial Evaluating the Effects of Preoperative and Postoperative Oral Nutritional Supplements (ONS) in Malnourished Post-gastrectomy Patients.
Ensure powder

Pancreatic Neoplasms, Biliary Tract Neoplasms, Pancreatitis, Chro Clinical Trial using pancreaticojejunostomy

Thomas Jefferson University - Recruiting 18 years or older.
- A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy.
pancreaticojejunostomy

Secondary Malignant Neoplasm of Liver, or Colorectal Neoplasms Clinical Trial using Open liver resection; Laparoscopic liver resection

Oslo University Hospital - Recruiting 18 years or older.
- Prospective Randomized Study of Laparoscopic Versus Open Liver Resection for Colorectal Metastases.
Open liver resection; Laparoscopic liver resection

Lung Neoplasms Clinical Trial

Sheba Medical Center - Recruiting N/A or older.
- .

Breast Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects.

Breast Neoplasms Clinical Trial using spiritual support; relaxation therapy

University of Sao Paulo - Recruiting 18 years or older.
- Effect of the Nursing Intervention 'Spiritual Support' in the Level of Spirituality and Clinical Parameters in Women With Breast Cancer: a Randomized Clinical Trial.
spiritual support; relaxation therapy

Hematologic Neoplasms Clinical Trial

Inje University - Recruiting N/A or older.
- Biomarker Research for Personalized Medicine in Blood Cancer Patient.

Bladder Cancer, Cancer, Bladder Neoplasms, or Urinary Bladder Can Clinical Trial

Lahey Clinic - Recruiting 18 years or older.
- Evaluation of Non-Invasive Assay(s) for the Detection of Bladder Cancer.

Breast Neoplasms Clinical Trial using Gadofosveset enhanced MRL of axillary lymph nodes

Maastricht University Medical Center - Recruiting 18 years or older.
- Non-invasive Nodal Staging in Breast Cancer With Magnetic Resonance Imaging Lymphography Using Gadofosveset.
Gadofosveset enhanced MRL of axillary lymph nodes

Stomach Neoplasms, Oesophageal Junction Cancer, or Lower Oesophag Clinical Trial using Epirubicin; Cisplatin; Paclitaxel; gastric surgery

Centre Hospitalier Universitaire de Besancon - Recruiting 18 years to 70 years.
- Preoperative Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel (Intensified PET) in Patients With Locally Gastric Cancer : a Phase II Proof-of-concept Study..
Epirubicin; Cisplatin; Paclitaxel; gastric surgery

Pancreatic Neoplasms Clinical Trial using 22 gauge ProCore needle biopsy; 25 gauge ProCore needle biopsy

Samsung Medical Center - Recruiting 18 years or older.
- Endoscopic Ultrasound-guided Fine Needle Tissue Acquisition With 22- and 25-gauge ProCore Needle in Solid Pancreatic and Peripancreatic Masses: A Prospective Comparative Study.
22 gauge ProCore needle biopsy; 25 gauge ProCore needle biopsy

Nasopharyngeal Neoplasms Clinical Trial using Cisplatin; Paclitaxel; IMRT

Chinese Academy of Medical Sciences - Recruiting 18 years to 70 years.
- Phase 2 Study of Inductive Plus Concurrent Chemoradiation Versus Concurrent Plus Adjuvant Chemoradiation for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT.
Cisplatin; Paclitaxel; IMRT

Breast Neoplasms Clinical Trial using Permanent breast seeds implant

Sunnybrook Health Sciences Centre - Recruiting 50 years or older.
- A Multicentre Registry Study of Permanent Breast Seed Implant (PBSI) for Early Stage Breast Cancers..
Permanent breast seeds implant

Breast Neoplasms Clinical Trial using Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Comparison of Carbon Nanotube X-ray Stationary Digital Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions..
Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner

Pancreatic Neoplasms, Biliary Tract Neoplasms, Pancreatitis, Chro Clinical Trial using pancreaticojejunostomy

Fudan University - Recruiting 18 years to 80 years.
- A Prospective Randomized Clinical Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy: Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy.
pancreaticojejunostomy

Colorectal Neoplasms, Neoplasm Metastasis, or Liver Neoplasms Clinical Trial using Cetuximab; chemotherapy of mFOLFOX6 or FOLFIRI

Fudan University - Recruiting 18 years to 75 years.
- Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer.
Cetuximab; chemotherapy of mFOLFOX6 or FOLFIRI

Hematologic Neoplasms Clinical Trial using Cyclophosphamide; Hematopoietic Stem Cell Transplantation,

European Institute of Oncology - Recruiting 18 years to 70 years.
- Nonmyeloablative Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies With Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression With Cyclophosphamide Administered Before and After Transplantation..
Cyclophosphamide; Hematopoietic Stem Cell Transplantation,

Mediastinal Lymphadenopathy, Hilar Lymphadenopathy, Lymphoma, Lun Clinical Trial using EBUS-TBNA

Azienda Ospedaliero, Universitaria Ospedali Riuniti - Recruiting 18 years or older.
- Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial..
EBUS-TBNA

Brain Neoplasms, Primary Malignant Clinical Trial

Universitaire Ziekenhuizen Leuven - Recruiting 18 years or older.
- Experiences and Needs of Patients With a High-grade Glioma and Their Caregivers.

Prostatic Neoplasms, Cancer of Prostate, Prostate Cancer, or Pros Clinical Trial using Laparoscopic Radical Prostatectomy (without a simulator); Laparoscopic Radical Prostatectomy (with a simulator)

Assistance Publique - H“pitaux de Paris - Recruiting N/A or older.
- A Prospective Randomized Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Online Simulator.
Laparoscopic Radical Prostatectomy (without a simulator); Laparoscopic Radical Prostatectomy (with a simulator)

Breast Neoplasms, Endocrine Breast Diseases, or Neoplasm Metastas Clinical Trial using letrozole; lapatinib; everolimus

University of Maryland - Recruiting 18 years or older.
- GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer.
letrozole; lapatinib; everolimus

Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Fa Clinical Trial using Bevacizumab; Paclitaxel; Carboplatin; specialized pathology review (Germany only)

AGO Study Group - Recruiting 18 years or older.
- A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer.
Bevacizumab; Paclitaxel; Carboplatin; specialized pathology review (Germany only)

Colonic Neoplasms Clinical Trial using Exercise Training; Usual Care

AHS Cancer Control Alberta - Recruiting 18 years or older.
- The Effects of Exercise Training on the Health-related Fitness of Colon Cancer Survivors: a Randomized Controlled Trial.
Exercise Training; Usual Care

Operable Breast Neoplasms Clinical Trial using letrozole (Femara)

Danish Breast Cancer Cooperative Group - Recruiting 60 years or older.
- Randomized Trial of Endocrine Therapy Against Locoregional Therapy First. A DBCG Trial in Postmenopausal Patients With Operable Hormone Receptor Positive Tumors Larger Than 2 cm..
letrozole (Femara)

Thoracic Neoplasms, or Non-small Cell Lung Cancer Clinical Trial using 3D conform radiotherapy

Chinese Academy of Medical Sciences - Recruiting 18 years to 70 years.
- Phase III Comparison of Postoperative 3D Conform Radiotherapy After Chemotherapy and Chemotherapy Alone in Patients With Completely Resected Stage IIIA(N2) Non-small Cell Lung Cancer.
3D conform radiotherapy

Liver Neoplasms Clinical Trial using Surgicelr absorbable Haemostat

Fudan University - Recruiting 18 years to 70 years.
- The Randomized Clinical Trial of Surgicelr Absorbable Haemostat Covering the Raw Cut Surface During the Hepatectomy.
Surgicelr absorbable Haemostat

Head and Neck Neoplasms Clinical Trial

Technische Universit„t Dresden - Recruiting 18 years to 70 years.
- Tumor Hypoxia of Head-and-neck Cancer Underwent Radiation Therapy Measured With F-18-FMISO.

Endometrial Neoplasms, or Neoplasm Metastasis Clinical Trial using Tumor biopsy study

University of Bergen - Recruiting N/A or older.
- Prospective Study of Endometrial Cancer Treatment in Relation to Molecular Markers in Curettage Specimens..
Tumor biopsy study

Breast Neoplasms, or Neoplasm Metastasis Clinical Trial

Beijing Cancer Hospital - Recruiting 18 years to 75 years.
- Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy.

Primary Glial Neoplasms of Brain, or Glioblastoma Clinical Trial using Aminolevulinic Acid

West Penn Allegheny Health System - Recruiting 18 years or older.
- A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Primary Glial Neoplasms of the Brain..
Aminolevulinic Acid

Head and Neck Neoplasms Clinical Trial

Montefiore Medical Center - Recruiting N/A or older.
- Molecular Classification of Head and Neck Tumors Using cDNA Microarray Analysis to Detect Prognosis and Response to Therapy.

Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Choriocarcin Clinical Trial

Huazhong University of Science and Technology - Recruiting 18 years to 75 years.
- A Large Multicentre Clinical Database and Biobank of Patients With Gynecologic Neoplasms.

Esophageal Neoplasms Clinical Trial

Maastricht Radiation Oncology - Recruiting 18 years or older.
- Consequences of Positron-Emission-Tomography/Computed Tomography (PET/CT) Based Radiotherapy Treatment Planning for Clinical Outcome in Esophageal Cancer Patients.

Carcinoma, Non-Small-Cell Lung, or Head and Neck Neoplasms Clinical Trial using [18F]-ML-10 in conjunction with PET imaging

Aposense Ltd. - Recruiting 18 years or older.
- A Prospective, Multicenter Study, to Evaluate the Efficacy and Safety of [18F]-ML-10, a Positron Emission Tomography (PET) Imaging Radiotracer, in Early Detection of Response of Non-Hematological Tumors to Concurrent Chemoradiotherapy.
[18F]-ML-10 in conjunction with PET imaging

Breast Neoplasms, Neoplasm Metastasis, Gene Expression Profiling, Clinical Trial using cytokine

Beijing Cancer Hospital - Recruiting 18 years to 75 years.
- Gene Expression Profiling of Breast Cancer Cells in Pleural Effusion Prodict the Response of Malignant Pleural Effusion to Immunotherapy.
cytokine

Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, or Clinical Trial using cetuximab (associated with radiotherapy); cisplatin (associated to radiotherapy)

Azienda USL 4 Prato - Recruiting 18 years or older.
- Multiinstitutional Open Label Randomized Phase II Study Comparing Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy as Firstline Treatment for Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-NHSCC).
cetuximab (associated with radiotherapy); cisplatin (associated to radiotherapy)

Colorectal Neoplasms Clinical Trial using sorafenib; FOLFIRI

Fudan University - Recruiting 18 years to 75 years.
- A Phase ? Open Label, Non Randomized Study, in Which Sorafenib is Used in Combination With Irinotecan, Leucovorin and Fluorouracil in Patients With Advanced Colorectal Cancer After Failure of Oxaliplatin Treatment.
sorafenib; FOLFIRI

Neoplasms Clinical Trial using Capecitabine, 5-fluorouracil

The Netherlands Cancer Institute - Recruiting 18 years or older.
- Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines.
Capecitabine, 5-fluorouracil

Lung Neoplasms Clinical Trial using gemcitabine, carboplatin; surgery

Hospital Authority, Hong Kong - Recruiting 18 years to 75 years.
- Phase II Study of the Response Rate of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small Cell Lung Cancer Before Surgery.
gemcitabine, carboplatin; surgery

Rectal Neoplasms Clinical Trial using Mesorectal excision with lateral lymph node dissection; Mesorectal excision without lateral lymph node excision

Japan Clinical Oncology Group - Recruiting 21 years to 74 years.
- Mesorectal Excision With Lateral Lymph Node Dissection Versus Without Lateral Lymph Node Dissection for Clinical Stage II, III Lower Rectal Cancer (JCOG0212).
Mesorectal excision with lateral lymph node dissection; Mesorectal excision without lateral lymph node excision

Brain Neoplasms, or Neoplasm Metastasis Clinical Trial using Whole brain radiation therapy arm; Salvage stereotactic radiosurgery arm

Japan Clinical Oncology Group - Recruiting 20 years to 79 years.
- Randomized Phase III Trial of Postoperative Whole Brain Radiation Therapy Compared With Salvage Stereotactic Radiosurgery in Patients With One to Four Brain Metastasis: Japan Clinical Oncology Group Study (JCOG 0504).
Whole brain radiation therapy arm; Salvage stereotactic radiosurgery arm

Colonic Neoplasms Clinical Trial using Therapeutic conventional colorectal surgery; Therapeutic laparoscopic colorectal surgery; Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest

University Hospital Dubrava - Recruiting 20 years to 80 years.
- Double Blinded Randomized Clinical Trial of the Effect of Open Versus Laparoscopic Colectomy on Neutrophils in Patients With Colon Cancer.
Therapeutic conventional colorectal surgery; Therapeutic laparoscopic colorectal surgery; Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest

Pancreas Neoplasms Clinical Trial using Docetaxel; Oxaliplatin

University of Ulm - Recruiting 18 years or older.
- Phase II Study: Docetaxel Plus Oxaliplatin as Second-line Therapy in Patients With Advanced Metastatic Pancreatic Cancer.
Docetaxel; Oxaliplatin

Gastrointestinal Neoplasms Clinical Trial

Komagome Hospital - Recruiting 20 years to 70 years.
- Bone Marrow-derived Cells' Contribution to Tumor Formation and Epithelial Cells Regeneration in the Gastrointestinal Tract.

Head and Neck Neoplasms, Head and Neck Cancer, Wounds, or Ulcer Clinical Trial using silver-releasing dressings

National Taiwan University Hospital - Recruiting 18 years or older.
- The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound.
silver-releasing dressings

Endometrial Neoplasms, Uterine Cervical Neoplasms, Ovarian Neopla Clinical Trial

Walter Reed Army Medical Center - Recruiting 18 years or older.
- Tissue and Data Acquisition Activity for the Study of Gynecological Disease.

Breast Neoplasms Clinical Trial using Contrast-enhanced MR mammography

UMC Utrecht - Recruiting 18 years to 75 years.
- MR Mammography: Randomized Controlled Trial to Study Efficiency of MR Mammography in Reducing the Number of Invasive Interventions in Nonpalpable Suspicious Breast Lesions. The MONET - Study.
Contrast-enhanced MR mammography

Esophageal Neoplasms, or Stomach Neoplasms Clinical Trial using Docetaxel, Oxaliplatin; Radiotherapy

Johannes Gutenberg University Mainz - Recruiting 18 years to 75 years.
- Prospective, Open, Multicentre Phase I/II Study to Evaluate the Safety and Efficacy of a Neoadjuvant Radiochemotherapy With Docetaxel and Oxalipaltin in Patients With Adenocarcinoma of the Gastric-Oesophageal Junction.
Docetaxel, Oxaliplatin; Radiotherapy

Stomach Neoplasms Clinical Trial using S-1,oxaliplatin

National Cancer Center, Korea - Recruiting 18 years or older.
- A Randomized Phase II Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma.
S-1,oxaliplatin

Stomach Neoplasms Clinical Trial using S-1,Docetaxel

National Cancer Center, Korea - Recruiting 18 years to 70 years.
- Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer.
S-1,Docetaxel

Prostatic Neoplasms Clinical Trial using Samarium Sm-153 lexidronam + Docetaxel

Cytogen Corporation - Recruiting N/A or older.
- Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer.
Samarium Sm-153 lexidronam + Docetaxel

Colonic Neoplasms Clinical Trial

Samsung Medical Center - Recruiting N/A or older.
- Establishing Effective Screening Methods for Diagnosing Hereditary Nonpolypoisis Colorectal Cancer.

Head and Neck Neoplasms Clinical Trial using BAY 43-9006

Jules Bordet Institute - Recruiting 18 years or older.
- .
BAY 43-9006

Colonic Neoplasms Clinical Trial using Indium labeled IMP-205xm734

Radboud University - Recruiting 18 years or older.
- Radioimmunodetection of CEA-Producing Tumors Using a Bispecific Antibody Pre-Targeting Method and an In-Labeled Peptide.
Indium labeled IMP-205xm734

Breast Neoplasms Clinical Trial using Docetaxel; Capecitabine; Docetaxel/Capecitabine

Georgia Center for Oncology Research & Education - Recruiting 18 years or older.
- Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer.
Docetaxel; Capecitabine; Docetaxel/Capecitabine

Oropharyngeal Neoplasms Clinical Trial using Cetuximab

Trial Form Support S.L. - Recruiting 18 years to 80 years.
- Open Label Randomized Phase II, Multicentre, Pilot Study to Evaluate Safety and Efficacy of the Combination of Cetuximab and Concomitant-Boost Accelerated Radiotherapy Followed or Not by a Complementary Treatment With Cetuximab in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma..
Cetuximab

Colorectal Cancer, Liver Neoplasms, Hepatocellular Carcinoma, Gal Clinical Trial using interventionally implanted hepatic arterial port catheter

Charite University, Berlin, Germany - Recruiting 18 years or older.
- Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms..
interventionally implanted hepatic arterial port catheter

Head and Neck Neoplasms Clinical Trial using Transamin

Taichung Veterans General Hospital - Recruiting 20 years to 80 years.
- If Tranexamic Acid Could Reduce the Duration of Drainage Tube Placement ? -A Prospective Randomized Study in Head and Neck Surgery Patients.
Transamin

Soft Tissue Neoplasms Clinical Trial

National Taiwan University Hospital - Recruiting N/A to 18 years.
- Retrospective Clinical Outcome Study of Pediatric Dermatofibrosarcoma Protuberans: Single Institutional Experience of Twelve Cases From 1977-2002.

Skin Neoplasms Clinical Trial

National Taiwan University Hospital - Recruiting N/A or older.
- Clinical Usefulness of Optical Skin Biopsy.

Lung Neoplasms Clinical Trial

National Taiwan University Hospital - Recruiting 20 years or older.
- .

Breast Neoplasms Clinical Trial

National Taiwan University Hospital - Recruiting 30 years or older.
- .